跳至主要内容
临床试验/NCT05839899
NCT05839899招募中3 期

Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location: A Randomized Pilot Study of Misoprostol Dosing

Planned Parenthood League of Massachusetts1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2023年8月30日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
50
试验地点
1
主要终点
Recruitment rates, to determine feasibility of recruitment

研究概览

简要总结

Patients who seek medication abortion early in pregnancy may have an ultrasound that does not show a pregnancy in the uterus. This is known as a "pregnancy of unknown location". These patients most likely have a pregnancy in the uterus that is too early to be seen on ultrasound, but it is possible that the pregnancy is not seen inside the uterus because it is outside of the uterus, known as an ectopic pregnancy. Patients with ectopic pregnancies are at risk for serious complications, and the medications used for medication abortion may not end an ectopic pregnancy.

Currently, at Planned Parenthood League of Massachusetts (PPLM), patients seeking medication abortion, including some patients with a pregnancy of unknown location, are given mifepristone to begin the medication abortion at the clinic and then one dose of misoprostol to take at home to cause the pregnancy to pass. However, research suggests that a second dose of misoprostol leads to a higher rate of completed abortion for certain patients.

This research is being conducted to learn if two doses of the at-home misoprostol during the medication abortion process leads to a higher rate of completed abortion for patients with pregnancy of unknown location. In this study, all participants will receive mifepristone as they normally would. Then, participants will be randomly assigned to receive either one dose of misoprostol or two doses of misoprostol.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Positive urine or serum hCG test
  • No evidence of gestational sac on transvaginal ultrasound
  • No evidence of ectopic pregnancy on transvaginal ultrasound
  • Desire for same-day start medication abortion as method of pregnancy termination
  • Eligible for same-day-start medication abortion based on PPLM clinical guidelines at the time of enrollment
  • English-speaking

排除标准

  • Ineligible for medication abortion at PPLM based on current PPLM clinical guidelines at the time of enrollment
  • o PPLM clinical guidelines for medication abortion currently exclude those with chronic adrenal failure, concurrent long-term corticosteroid use, hemorrhagic disorders or concurrent anti-coagulation, porphyria, allergies to mifepristone or misoprostol, or an IUD in place.
  • Ineligible for same-day-start medication abortion with PUL based on PPLM clinical guidelines and clinician assessment at the time of enrollment
  • o PPLM clinical guidelines for initiating medication abortion with PUL currently exclude those with major ectopic risk factors (IUD in situ, prior ectopic, history of tubal surgery) or symptoms concerning for ectopic (i.e. pain, bleeding) per clinician discretion.
  • Age less than 18 years old
  • Prior participation in this study
  • Anticipated inability to adhere to follow up protocol or complete the survey
  • Unable to give informed consent or to complete all study procedures

研究组 & 干预措施

Mifepristone plus Single dose misoprostol

Active Comparator

Participant will take mifepristone, then one dose of misoprostol at home to pass the pregnancy (current routine abortion care).

干预措施: Mifepristone plus one dose Misoprostol (Drug)

Mifepristone plus two doses misoprostol

Experimental

Participant will take mifepristone, then at home will take two doses of misoprostol 4 hours apart to pass the pregnancy.

干预措施: Mifepristone plus two doses Misoprostol (Drug)

结局指标

主要结局

Recruitment rates, to determine feasibility of recruitment

时间窗: 1 year

Feasibility of recruitment will be assessed by the recruitment and refusal rates. The recruitment rate will be calculated by dividing the total number of participants recruited by the number of months spent for recruitment.

Refusal rates, to determine feasibility of recruitment

时间窗: 1 year

Feasibility recruitment will be assessed by the recruitment and refusal rates. The refusal rate will be calculated by dividing the total number of participants recruited by the number of patients approached for study participation..

Acceptability of second dose of misoprostol

时间窗: 1 month per subject, 1 year for all subjects

Acceptability of this regimen will be assessed by measuring how often patients assigned to the treatment arm actually take the second dose of misoprostol. If 13 or more patients in the double-miso group (\>50%) do not take the second dose, this will be considered unacceptable.

次要结局

未报告次要终点

研究者

发起方
Planned Parenthood League of Massachusetts
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验